Skip to main content
Erschienen in: Advances in Therapy 4/2023

22.02.2023 | Original Research

Association Between Multidrug-Resistant Bacteria and Mortality in Critically Ill Patients

verfasst von: Gary Duclos, Ines Lakbar, Mohamed Boucekine, Georges Lolo, Nadim Cassir, Marc Leone

Erschienen in: Advances in Therapy | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Multidrug-resistant bacteria (MDRB) carriage may impact the outcomes of intensive care unit (ICU) patients. In this study, we aimed to assess the effect of MDRB-related infection and colonization on the day 60 mortality rate.

Methods

We conducted a retrospective, observational study in a single university hospital ICU. From January 2017 to December 2018, we screened all patients admitted to the ICU for at least 48 h for MDRB carriage. The primary outcome was the mortality rate on day 60 after MDRB-related infection. The secondary outcome was the mortality rate on day 60 of non-infected but colonized patients with MDRB. We considered the effect of potential confounders, such as the occurrence of septic shock, inadequate antibiotic therapy, Charlson score, and life-sustaining limitation order.

Results

We included 719 patients during the aforementioned period; of this number, 281 (39%) had a microbiologically documented infection. MDRB was found in 40 (14%) patients. The crude mortality rate in the MDRB-related infection group was 35% vs. 32% in the non-MDRB-related infection group (p = 0.1). Logistic regression showed that MDRB-related infection was not associated with excess mortality, with an odds ratio of 0.52 and a 95% confidence interval from 0.17 to 1.39 (p = 0.2). Charlson score, septic shock, and life-sustaining limitation order were significantly associated with an increased mortality rate on day 60. No effect of MDRB colonization on mortality rate on day 60 was highlighted.

Conclusion

MDRB-related infection or colonization was not associated with an increased mortality rate on day 60. Other confounders, such as comorbidities, may account for a higher mortality rate.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–98.CrossRefPubMed Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–98.CrossRefPubMed
2.
Zurück zum Zitat Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.CrossRefPubMedPubMedCentral Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Rottier WC, Ammerlaan HSM, Bonten MJM. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67(6):1311–20.CrossRefPubMed Rottier WC, Ammerlaan HSM, Bonten MJM. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67(6):1311–20.CrossRefPubMed
4.
Zurück zum Zitat Lakbar I, Medam S, Ronflé R, et al. Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia. Sci Rep. 2021;11(1):16497.CrossRefPubMedPubMedCentral Lakbar I, Medam S, Ronflé R, et al. Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia. Sci Rep. 2021;11(1):16497.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Lambert M-L, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis. 2011;11(1):30–8.CrossRefPubMed Lambert M-L, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis. 2011;11(1):30–8.CrossRefPubMed
6.
Zurück zum Zitat Paramythiotou E, Routsi C. Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients. World J Crit Care Med. 2016;5(2):111.CrossRefPubMedPubMedCentral Paramythiotou E, Routsi C. Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients. World J Crit Care Med. 2016;5(2):111.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Blanco N, Harris AD, Rock C, et al. Risk factors and outcomes associated with multidrug-resistant Acinetobacter baumannii upon intensive care unit admission. Antimicrob Agents Chemother. 2018;62(1):e01631-e1717.CrossRefPubMed Blanco N, Harris AD, Rock C, et al. Risk factors and outcomes associated with multidrug-resistant Acinetobacter baumannii upon intensive care unit admission. Antimicrob Agents Chemother. 2018;62(1):e01631-e1717.CrossRefPubMed
8.
Zurück zum Zitat Zheng Y, Xu N, Pang J, et al. Colonization with extensively drug-resistant Acinetobacter baumannii and prognosis in critically ill patients: an observational cohort study. Front Med. 2021;8: 667776.CrossRef Zheng Y, Xu N, Pang J, et al. Colonization with extensively drug-resistant Acinetobacter baumannii and prognosis in critically ill patients: an observational cohort study. Front Med. 2021;8: 667776.CrossRef
9.
Zurück zum Zitat Giarratano A, Green SE, Nicolau DP. Review of antimicrobial use and considerations in the elderly population. Clin Interv Aging. 2018;13:657–67.CrossRefPubMedPubMedCentral Giarratano A, Green SE, Nicolau DP. Review of antimicrobial use and considerations in the elderly population. Clin Interv Aging. 2018;13:657–67.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Calandra T, Cohen J, International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The International Sepsis Forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33(7):1538–48. Calandra T, Cohen J, International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The International Sepsis Forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33(7):1538–48.
11.
Zurück zum Zitat Toulouse E, Lafont B, Granier S, Mcgurk G, Bazin J-E. French legal approach to patient consent in clinical research. Anaesth Crit Care Pain Med. 2020;39(6):883–5.CrossRefPubMed Toulouse E, Lafont B, Granier S, Mcgurk G, Bazin J-E. French legal approach to patient consent in clinical research. Anaesth Crit Care Pain Med. 2020;39(6):883–5.CrossRefPubMed
12.
Zurück zum Zitat von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.CrossRef von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.CrossRef
13.
Zurück zum Zitat Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.CrossRefPubMed Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.CrossRefPubMed
14.
Zurück zum Zitat Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):775.CrossRefPubMedPubMedCentral Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):775.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0, 2018. http://www.eucast.org. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0, 2018. http://​www.​eucast.​org.
16.
Zurück zum Zitat Leangapichart T, Gautret P, Griffiths K, et al. Acquisition of a high diversity of bacteria during the Hajj Pilgrimage, including Acinetobacter baumannii with blaOXA-72 and Escherichia coli with blaNDM-5 carbapenemase genes. Antimicrob Agents Chemother. 2016;60(10):5942–8.CrossRefPubMedPubMedCentral Leangapichart T, Gautret P, Griffiths K, et al. Acquisition of a high diversity of bacteria during the Hajj Pilgrimage, including Acinetobacter baumannii with blaOXA-72 and Escherichia coli with blaNDM-5 carbapenemase genes. Antimicrob Agents Chemother. 2016;60(10):5942–8.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
18.
Zurück zum Zitat Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.CrossRefPubMed Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.CrossRefPubMed
19.
Zurück zum Zitat Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.CrossRefPubMed Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.CrossRefPubMed
20.
Zurück zum Zitat Suissa S, Ernst P. Bias in observational study of the effectiveness of nasal corticosteroids in asthma. J Allergy Clin Immunol. 2005;115(4):714–9.CrossRefPubMed Suissa S, Ernst P. Bias in observational study of the effectiveness of nasal corticosteroids in asthma. J Allergy Clin Immunol. 2005;115(4):714–9.CrossRefPubMed
21.
Zurück zum Zitat Samet JM. Measuring the effectiveness of inhaled corticosteroids for COPD is not easy! Am J Respir Crit Care Med. 2003;168(1):1–2.CrossRefPubMed Samet JM. Measuring the effectiveness of inhaled corticosteroids for COPD is not easy! Am J Respir Crit Care Med. 2003;168(1):1–2.CrossRefPubMed
22.
Zurück zum Zitat Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1):49–53.CrossRefPubMed Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1):49–53.CrossRefPubMed
23.
Zurück zum Zitat Denis J-B, Lehingue S, Pauly V, et al. Multidrug-resistant Pseudomonas aeruginosa and mortality in mechanically ventilated ICU patients. Am J Infect Control. 2019;47(9):1059–64.CrossRefPubMed Denis J-B, Lehingue S, Pauly V, et al. Multidrug-resistant Pseudomonas aeruginosa and mortality in mechanically ventilated ICU patients. Am J Infect Control. 2019;47(9):1059–64.CrossRefPubMed
24.
Zurück zum Zitat Masse J, Elkalioubie A, Blazejewski C, et al. Colonization pressure as a risk factor of ICU-acquired multidrug resistant bacteria: a prospective observational study. Eur J Clin Microbiol Infect Dis. 2017;36(5):797–805.CrossRefPubMed Masse J, Elkalioubie A, Blazejewski C, et al. Colonization pressure as a risk factor of ICU-acquired multidrug resistant bacteria: a prospective observational study. Eur J Clin Microbiol Infect Dis. 2017;36(5):797–805.CrossRefPubMed
25.
Zurück zum Zitat On behalf of the VIP1 study group, Flaatten H, De Lange DW, et al. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years). Intensive Care Med. 2017;43(12):1820–28. On behalf of the VIP1 study group, Flaatten H, De Lange DW, et al. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years). Intensive Care Med. 2017;43(12):1820–28.
26.
Zurück zum Zitat Muscedere J, Waters B, Varambally A, et al. The impact of frailty on intensive care unit outcomes: a systematic review and meta-analysis. Intensive Care Med. 2017;43(8):1105–22.CrossRefPubMedPubMedCentral Muscedere J, Waters B, Varambally A, et al. The impact of frailty on intensive care unit outcomes: a systematic review and meta-analysis. Intensive Care Med. 2017;43(8):1105–22.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Medam S, Zieleskiewicz L, Duclos G, et al. Risk factors for death in septic shock: a retrospective cohort study comparing trauma and non-trauma patients. Medicine (Baltimore). 2017;96(50):e9241.CrossRefPubMed Medam S, Zieleskiewicz L, Duclos G, et al. Risk factors for death in septic shock: a retrospective cohort study comparing trauma and non-trauma patients. Medicine (Baltimore). 2017;96(50):e9241.CrossRefPubMed
Metadaten
Titel
Association Between Multidrug-Resistant Bacteria and Mortality in Critically Ill Patients
verfasst von
Gary Duclos
Ines Lakbar
Mohamed Boucekine
Georges Lolo
Nadim Cassir
Marc Leone
Publikationsdatum
22.02.2023
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 4/2023
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-023-02448-7

Weitere Artikel der Ausgabe 4/2023

Advances in Therapy 4/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.